Regenxbio (RGNX) EBT (2014 - 2025)

Regenxbio's EBT history runs 12 years deep, the most recent figure standing at $89.8 million for Q4 2025.

• On a quarterly basis, EBT rose 234.83% year-over-year to $89.8 million in Q4 2025; TTM through Dec 2025 was -$43.0 million, a 83.11% increase from a year earlier, with the FY2025 full-year figure at -$535.6 million, down 135.82% from the prior year.
• EBT advanced to $89.8 million in Q4 2025 per RGNX's latest filing, from -$65.5 million in the prior quarter.
• Across five years, EBT topped out at $307.4 million in Q4 2021 and bottomed at -$76.8 million in Q1 2022.
• The 5-year median for EBT is -$62.4 million (2023), against an average of -$21.0 million.
• Biggest YoY gain for EBT was 859.11% in 2021; the steepest drop was 764.6% in 2021.
• Year by year, EBT stood at $307.4 million in 2021, then retreated by 28.32% to $220.4 million in 2022, then plunged by 128.58% to -$63.0 million in 2023, then decreased by 5.8% to -$66.6 million in 2024, then surged by 234.83% to $89.8 million in 2025.
• Per Business Quant, the three latest RGNX EBT figures stand at $89.8 million (Q4 2025), -$65.5 million (Q3 2025), and -$70.9 million (Q2 2025).